Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
NCT04262830
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cardiotoxicity
- Pediatric Cancer
- Heart Failure
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 13 to 39 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hari Narayan
- Last updated on ClinicalTrials.gov
- January 28, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Rady Children's Hospital · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.